6 Jun 17

Blood vessel-blocking medication slows prostate tumor progression: Experts A blood vessel-blocking medication called tasquinimod slowed the price of disease progression in a clinical trial of 200 prostate cancer sufferers, according to professionals at Johns Hopkins, Roswell Park Malignancy Duke and Institute University. Tasquinimod can be a so-called anti-angiogenesis medication that squeezes off blood circulation to prostate tumors by blocking fresh blood vessel advancement. Tumors require these huge networks of arteries to supply nutrition.Olfactomedin-4, also called Olfm4, places the brakes on the power of the white blood cells to rapidly react to and destroy bacteria. As a result, if one deletes the proteins, one has a more efficient method of killing a multitude of bacteria. We’d shown in previous studies these bacteria include fairly common bacterias: Staphylococcus aureus, E. Coli, Klebsiella, and Helicobacter, for instance. What we didn't know is if the white bloodstream cells were killing these bacteria solely through these pathways, or whether maybe it included this oxidative system also.